

<0.0001). Diffusion restriction (qualitatively) was uncommon but only seen in *BRAF* V600E ($p=0.0042$) with lower ADC ratio (quantitatively) ($p=0.003$). Additionally, *BRAF* V600E mutant tumors appeared more infiltrative than *BRAF* fusion and wild-type ($p=0.0002$). **CONCLUSION:** *BRAF* fusion and *BRAF* V600E mutant pLGG have unique imaging features that can be used to differentiate from each other and wild-type pLGG using standard radiology review with high inter-reader agreement. In the era of targeted therapy, these features can be useful for therapeutic planning prior to surgery.

LGG-09. A NATIONWIDE SERVICE EVALUATION OF SAFETY, RADIOLOGIC AND VISUAL OUTCOME REFINING BEVACIZUMAB-BASED TREATMENTS IN CHILDREN WITH PROGRESSIVE LOW-GRADE GLIOMA

Katherine Green¹, Paraskevi Panagopoulou^{1,2}, Felice D'Arco³, Patricia O'Hare^{4,5}, Richard Bowman¹, Bronwen Walters⁴, Christine Dahl¹, Mette Jorgensen¹, Pritesh Patel¹, Olga Slater¹, Rehana Ahmed⁵, Simon Bailey⁶, Fernando Carceller⁷, Rhiannon Collins⁸, Elizabeth Corley⁷, Martin English⁹, James Hayden¹⁰, Lisa Howells¹⁰, Ahmed Kamal⁹, John Paul Kilday¹¹, Stephen Lewis¹², Blanche Lumb¹³, Thomas Micić¹³, Dip Mitra⁶, Erika pace⁷, Susan Picton¹⁴, Barry Pizer¹⁰, Ayad Shafiq¹⁵, Lena Uzunova¹³, Shaun Wilson⁸, Harriet Wayman¹¹, Darren Hargrave¹, Enrico Opocher^{1,16}; ¹Great Ormond Street Hospital, London, United Kingdom. ²Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece. ³Great Ormond Street, London, United Kingdom. ⁴Children's Hospital Belfast, Belfast, United Kingdom. ⁵Nottingham Children's Hospital, Nottingham, United Kingdom. ⁶Great North Children's Hospital, Newcastle, United Kingdom. ⁷Royal Marsden Hospital, London, United Kingdom. ⁸John Radcliffe Hospital, Oxford, United Kingdom. ⁹Birmingham Children's Hospital, Birmingham, United Kingdom. ¹⁰Alderhey Children's Hospital, Liverpool, United Kingdom. ¹¹Royal Manchester Children's Hospital, Manchester, United Kingdom. ¹²Bristol Children's Hospital, Bristol, United Kingdom. ¹³Noah's Ark Children's Hospital Wales, Cardiff, United Kingdom. ¹⁴Leeds Children's Hospital, Leeds, United Kingdom. ¹⁵Great North Children's Hospital, Newcastle, United Kingdom. ¹⁶Padua University Hospital, Padua, Italy

INTRODUCTION: Bevacizumab/Irinotecan is currently 3rd-line treatment in the UK for progressive Paediatric Low-Grade Glioma (pLGG) based on limited evidence. A nationwide service evaluation was conducted to review its safety and efficacy amongst a larger cohort. **METHODS:** Data from children with pLGG receiving Bevacizumab-based Treatments (BBT) from 11 UK Centres (2009-2020) were reviewed. Radiological and visual outcomes were based on standardized measurements. Clinical-radiological correlation was investigated. Time to progression from BBT stop, progression free-survival (PFS) curves and multivariate analysis of prognostic factors ($p < 0.05$) were performed. **RESULTS:** 88 children with pLGG (88% OPG, 24% NF1) had BBT for radiological (43%), visual (20%) or combined (27%) progression, after 40 months (median) from diagnosis. Amongst OPG cases, visual acuity (VA) per eye (better/worse) before BBT was logMAR 0.0-0.3 (23/7) 0.3 - 1.0 (27/20), > 1.0 (14/18) and LP/NLP (8/27), with 19/8 children respectively blind (LP/NLP) in one or both eyes. Bevacizumab 10 mg/kg every 14 days (median 24 doses) was given as 3rd line+ with Irinotecan (85%) or alongside 1st/2nd line chemo (15%) leading to remarkable radiological (88%) and visual (74%) responses (stable or improved) within 3-6 months, with limited toxicity. 12% progressed on treatment, and 8% died unrelated to BBT. After initial response 65% progressed at a median of 8 months (4-23) after BBT, resulting in 3-year-all-causes-PFS of 16% and 3-yr-visual-PFS of 45% from start of BBT. Visual concordance with MRI was poor (36%) but increases (47%) when better-eye determines visual outcome. Lack of NF1 and diencephalic syndrome (DS) at presentation were independent negative prognostic factors for PFS. **CONCLUSIONS:** A remarkable but transient effect of BBT has been confirmed. Visual > radiological responses can be sustained after BBT. Variations in current BBT strategies justifies further research, including the potential upfront use alongside conventional first-line chemotherapy as sight-saving strategy.

LGG-10. EVALUATION OF THE CHEMOTHERAPY EFFICACY OF CHILDREN WITH OPTIC PATHWAY GLIOMA IN A TERTIARY HOSPITAL IN CHINA

Miao Li¹, Shuxu Du¹, Yongji Tian², Jin Zhang¹, Wenchao Gao¹, Jinjing Xiao³, Xiaojun Gong¹, Yanling Sun¹, Wanshui Wu¹, Liming Sun¹; ¹Beijing Shijitan Hospital, Capital Medical University, Beijing, China. ²Beijing Tiantan Hospital, Capital Medical University, Beijing, China. ³Zhengzhou University, Zhengzhou, China

OBJECTIVE: In order to analyze the chemotherapy efficacy of children with optic pathway glioma (OPG), the clinical, treatment and prognosis factors of children with OPG who received the German International Society of Pediatric Oncology (SIOP) low-grade glioma (LGG) 2004 regimen chemotherapy, were retrospectively analyzed. **METHOD:** From September 2014 to October 2019, a total of 60 patients with OPG were enrolled and accept

LGG 2004 chemotherapy in the Department of Pediatrics, Beijing Shijitan Hospital, Capital Medical University, China. The progression-free survival (PFS) rates and overall survival (OS) rates were analyzed by the Kaplan-Meier method. Both univariate and multivariate analyses were performed using the Cox-proportional hazards model. The test standard $\alpha=0.05$. **RESULTS:** Until January 1st, 2022, all children were alive, and the clinical symptoms were improved at any degree, and well tolerated during the whole treatment. The median follow-up time was 3.7 years (range 2.3-7.1 years), the average time of objective response was 6.8 months (range from 2 to 21 months), and the 5 year PFS rates were $73.0 \pm 7.24\%$. However, about 3 to 8 months later, 8 cases (age <4 years) relapsed which attained partial remission (PR) at the end of the whole therapy. These relapsed cases were performed the LGG 2004 regimen again, and all had an objective response after 4-6 courses of treatment. In addition, two children (age>8 years old) progressed rapidly during treatment, and had to be performed local radiotherapy and reached complete remission (CR). Another two cases with *BRAF* V600E mutation, reached a significant remission after 3 months of targeted therapy with selumetinib. Furthermore, the COX multivariate analysis shows that spinal metastasis is an independent risk factor of prognosis of children with OPG. **CONCLUSIONS:** Chemotherapy can improve the clinical efficacy of children with OPG, which is better when combining with bevacizumab and/or targeted therapy.

LGG-11. ANALYSIS OF NEUROSURGICAL COMPLICATIONS IN PEDIATRIC SUPRATENTORIAL MIDLINE LOW-GRADE GLIOMA – RESULTS FROM THE GERMAN LGG STUDIES

Sarah Weiß¹, Matthias Schulz², Daniela Kandels³, Pablo Hernáiz Driever¹, Olaf Witt⁴, Ulrich-Wilhelm Thomale², Astrid Gnekow³, Michèle Simon¹; ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Pediatric Oncology and Hematology, Berlin, Germany. ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Pediatric Neurosurgery, Berlin, Germany. ³Swabian Children's Cancer Center, Faculty of Medicine, University Augsburg, Augsburg, Germany. ⁴Hopp Children's Cancer Center Heidelberg (KiTZ), Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg University Hospital, Heidelberg, Germany

OBJECTIVE: Around 80% of all pediatric low-grade glioma (LGG) patients undergo at least one tumor surgery. Interventions in the supratentorial midline (SML) are particularly challenging due to the proximity of eloquent areas, yet associated complications are scarcely reported. We investigated the frequency of neurosurgical complications and related impairments and aimed at identifying risk factors for their appearance related to patient characteristics or the procedure. **PATIENTS AND METHOD:** Records were retrospectively analyzed from 321 patients with SML-LGG from the successive multicenter German LGG studies, who underwent neurosurgery at 63 hospitals between May 12th, 1998 and June 27th, 2020. **RESULTS:** 543 operations (235 resections, 168 biopsies, 140 non-tumor interventions) were performed on 321 patients (54% male, median age 9 years, 11% NF1 positive, 43% visual pathway glioma). Surgical mortality rate was 0,93% ($n=3$). Applying the Drake classification postoperative surgical morbidity was observed in 259 cases (47,7%), medical morbidity in 103 cases (19%). 30-day persistence rate of newly developed neurological deficits was 44,8% (65/165 cases); neuroendocrine impairment affected 57 patients (17,8%), visual deterioration 34 (10,6%). Complications/impairments following resections were associated with patient age below 3 years at operation, tumor volume above 80 cm³, presence of hydrocephalus prior to surgery, complete resection, intervention in centers with fewer reported resections and surgery performed between 1998-2006 by univariate analysis. In contrast, the neurosurgical approach, tumor location, NF1 status as well as previous antineoplastic treatment were not associated with the frequency of complications. Regarding biopsies, open biopsies showed significantly more surgery-associated complications/impairments compared with stereotactic procedures. **CONCLUSIONS:** Neurosurgery-associated complications and impairments were frequent in pediatric patients with supratentorial midline LGG undergoing open surgery in the German LGG-studies. We identified six patient- and institution-associated factors that may increase the risk for surgical complications. Skills at the treating center and extent of resection should be considered appropriately prior to intervention.

LGG-13. THE CLINICAL AND MOLECULAR CHARACTERISTICS OF PROGRESSIVE HYPOTHALAMIC/OPTIC PATHWAY Pilocytic ASTROCYTOMA

Xiaoyu Li¹, Daniel Moreira¹, Asim Bag¹, Ibrahim Qaddoumi¹, Sahaja Acharya², Jason Chiang¹; ¹St. Jude, Memphis, TN, USA. ²Johns Hopkins University, Baltimore, MD, USA

Unresectable hypothalamic/optic pathway pilocytic astrocytoma (PA) can be challenging to manage due to repeated progressions despite mul-